title: Good clinical and radiological response to BRAF inhibitor in patient with metastatic thin melanoma.
abstract: The authors herein report the case of a 32-year-old man with advancing metastatic malignant melanoma, who has progressed through all previous lines of therapy, presenting with ongoing respiratory tract symptoms of exertional shortness of breath and cough. CT restaging confirmed clinical findings of deteriorating pulmonary disease; histological review revealed V600E BRAF mutation. He was started on targeted biological therapy with BRAF inhibitor GSK2118436, and is having a good clinical and radiological response without significant lasting toxicity.
authors: Medical Oncology Department, Mid-Western Regional Hospital, and Stokes Research Institute, University of Limerick, Limerick, Ireland. keithi.quintyne@hse.ie
authors: Keith Ian
authors: KI
authors: Quintyne
authors: Shirley
authors: S
authors: Baker
authors: Fintan
authors: F
authors: Wallis
authors: Rajnish
authors: R
authors: Gupta
mesh_terms: D000328:Adult; D019583:Dose Fractionation, Radiation; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D008297:Male; D008545:Melanoma / Q000235:genetics / Q000556:secondary / Q000628:therapy*; D010091:Oximes / Q000627:therapeutic use*; D011013:Pneumonectomy; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors* / Q000235:genetics; D012878:Skin Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*
chemical_list: D007093:Imidazoles; D010091:Oximes; D047428:Protein Kinase Inhibitors; D048493:Proto-Oncogene Proteins B-raf; C561627:dabrafenib